Atea Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
AVIR
CUSIP
04683R106
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 04683R106 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
15.0% 5/6/2026
Event 3/31/2026
Jean-Pierre Sommadossi 13G/A
10.1% 5/14/2025
Event 3/31/2025
BML Investment Partners, L.P. 13G
9.9% 2/9/2026
Event 12/31/2025
BlackRock, Inc. 13G/A 7.1% 4/23/2025
Event 3/31/2025
Tang Capital Management LLC 13G
6.0% 10/6/2026
Event 10/6/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Radoff Bradley Louis 13D/A
4.0% 4/17/2025
Event 4/16/2025
EcoR1 Capital, LLC 13G/A
4.0% 2/14/2025
Event 12/31/2024
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 12 392 k $2.04 M
2026 Q2 127 59.4 M $277 M
2026 Q1 130 60.1 M $323 M
2025 Q4 114 57.3 M $204 M
2025 Q3 123 53.8 M $156 M
2025 Q2 110 52.9 M $190 M
2025 Q1 110 53.0 M $158 M
2024 Q4 112 56.3 M $189 M
2024 Q3 113 58.0 M $194 M
2024 Q2 112 57.1 M $189 M
2024 Q1 122 55.3 M $223 M
2023 Q4 119 55.8 M $170 M
2023 Q3 127 57.0 M $171 M
2023 Q2 139 57.0 M $213 M
2023 Q1 135 57.0 M $191 M
2022 Q4 140 59.8 M $288 M
2022 Q3 132 57.5 M $327 M
2022 Q2 136 57.6 M $409 M
2022 Q1 145 55.2 M $398 M
2021 Q4 169 53.6 M $479 M
2021 Q3 159 56.8 M $1.99 B
2021 Q2 115 61.2 M $1.31 B
2021 Q1 87 52.5 M $3.23 B
2020 Q4 70 49.9 M $2.07 B